CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr | ₹4,591 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹5,484 Cr |
| Mar2024 | ₹5,246 Cr |
| Mar2023 | ₹5,033 Cr |
| Mar2022 | ₹4,913 Cr |
| Mar2021 | ₹4,591 Cr |
How is Total Current Liabilities of CIPLA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,484 Cr | 4.54 | |
| Mar2024 | ₹5,246 Cr | 4.22 | |
| Mar2023 | ₹5,033 Cr | 2.45 | |
| Mar2022 | ₹4,913 Cr | 7.01 | |
| Mar2021 | ₹4,591 Cr | - | |
Compare Total Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹121,170.0 Cr | 0.7% | -2.4% | 4.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹427,753.0 Cr | -0.2% | 1.1% | -0.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,091.0 Cr | 0.7% | -2.9% | 6.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹127,169.0 Cr | -0.9% | -1.6% | 13.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,165.0 Cr | 2.2% | 2.8% | 2.8% | Stock Analytics | |
| MANKIND PHARMA | ₹86,953.3 Cr | -1.9% | -6.2% | -19.2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 0.7% |
-2.4% |
4.2% |
| SENSEX | 0% |
0.1% |
3.9% |
You may also like the below Video Courses